I
I-MAB D
D
IMAB
2.00000
USD
0.32
(19.05%)
مغلق
حجم التداول
0
الربح لكل سهم
-0
العائد الربحي
-
P/E
-4
حجم السوق
163,320,692
الأخبار المقالات
العنوان: I/MAB
القطاع: Healthcare
الصناعة: Biotechnology
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).